Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-03-14
2006-03-14
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S649000
Reexamination Certificate
active
07012099
ABSTRACT:
The invention relates to the use of substituted 4-amino-1-phenylbutan-2-ol compounds in the form of their racemates, enantiomers, diastereomers or corresponding bases or corresponding salts of physiologically acceptable acids as regulators for the nociceptin/orphanin-FQ ligand ORL1 receptor system and for the production of medicaments.
REFERENCES:
patent: 6410790 (2002-06-01), Sundermann et al.
patent: 1 043 307 (2000-10-01), None
patent: 92 05169 (1992-04-01), None
patent: 99 46492 (1999-09-01), None
European Journal of Organic Chemistry (1988), vol. 10, pp. 2185-2191.
Post-Herpetic Nerualgia: Diagnosis & Treatment, The Pain Management Letter, A quarterly Report on Techniques & Treatmetns in Pain Management, Summer, 1997.
Neurontin Significantly Reduces Chronic Neuropathic Pain, Doctor's Guide, Dec. 23, 1998, URL:http://www.pslgroup.com/dg/D6AC6.htm.
R. Ihl et al.: “Zur nootropikabewertung fuer die praxis” NERVENARZT, vol. 68, No. 11, pp. 853-861 Nov. 1997.
R. Bertorelli et al.: “Nociceptin/orphanin FQ and its receptor: a potential target for drug discovery” Trends in Pharmacological Sciences, vol. 21, No. 7, pp. 233-234 Jul. 1, 2000.
D. Moelm, et al., Eur. J. Org. Chem., vol. 10, pp. 2185-2191, “Fragmentation Reactions of Quaternized γ-Amino Alcohols—Diastereoselective Synthesis of Highly Functionalized Oxetanes and Unsaturated Aldehydes and Ketones With a (Z)-C—C Double Bond”, 1998.
F. A. Abdulla, et al., The Journal of Neuroscience, vol. 18, No. 23, pp. 9685-9694, “Axotomy Reduces the Effect of Analgesic Opioids Yet Increases the Effect of Nociceptin on Dorsal Root Ganglion Neurons”, Dec. 1, 1998.
A. Ardati, et al., Molecular Pharmacology, vol. 51, pp. 816-824, “Interaction of [3H]Orphanin FQ and125I-Tyr14-Orphanin FQ With the Orphanin FQ Receptor: Kinetics and Modulation by Cations and Guanine Nucleotides”, 1997.
M. Arend, et al., SYNLETT, pp. 974-976, “A Simple and Highly Diastereoselective One-Pot Synthesis of Mannich-Bases”, Aug. 1997.
R. Carlson, et al., Acta Chemica Scandinavica B, vol. 38, pp. 49-53, “Improved Titanium Tetrachloride Procedure for Enamine Synthesis. II. Scope of the Reaction”, 1984.
H. C. Champion, et al., Biochemical and Biophysical Research Communications, vol. 234, No. 2, pp. 309-312, “[Tyr1]-Nociceptin, a Novel Nociceptin Analog, Decreases Systemic Arterial Pressure by a Naloxone-Insensitive Mechanism in the Rat”, 1997.
M. Connor, et al., British Journal of Pharmacology, vol. 118, pp. 205-207, “The Effect of Nociceptin on Ca2+Channel Current and Intracellular Ca2+in the SH-SY5Y Human Neuroblastoma Cell Line”, 1996.
T. Darland, et al., TINS, vol. 21, No. 5, pp. 215-221, “Orphanin FQ/Nociceptin: A Role in Pain and Analgesia, But So Much More”, 1998.
E. S. L. Faber, et al., British Journal of Phamacology, vol. 119, pp. 189-190, “Depression of Glutamatergic Transmission by Nociceptin in the Neonatal Rat Hemisected Spinal Cord Preparation in Vitro”, 1996.
B. Gumusel, et al., Life Sciences, vol. 60, No. 8, pp. PL-141 to PL-145, “Nociceptin: An Endogenous Agonist for Central Opioid Like1(ORL1) Receptors Possesses Systemic Vasorelaxant Properties”, 1997.
R. Gutierez, et al., Society for Neuroscience, 28thAnn. Meet., vol. 24, p. 1358, “Inhibition of Kindling Development by Nociceptin/Orphanin FQ”, 1998 (Abstract only).
N. Hara, et al., British Journal of Phamacology, v ol. 121, pp. 401-408, “Characterization of Nociceptin Hyperalgesia and Allodynia in Conscious Mice”, 1997.
G. Helmchen, et al., Methods of Organic Chemistry, vol. E 21 b, pp. 1925-1929, “Stereoselective Synthesis”, 1995.
F. Jenck, et al., Proc. Natl. Acad. Sci. USA, vol. 94, pp. 14854-14858, “Orphanin FQ Acts as an Anxiolytic to Attenuate Behavioral Responses to Stress”, Dec. 1997.
D. R. Kapusta, et al., Life Sciences, vol. 60, No. 1, pp. PL-15 to PL-21, “Diuretic and Antinatriuretic Responses Produced by the Endogenous Opioid-Like Peptide, Nociceptin (Orphanin FQ)”, 1997.
M. A. King, et al., Neuroscience Letters, vol. 223, pp. 113-116, “Spinal Analgesic Activity of Orphanin FQ/Nociceptin and its Fragments”, 1997.
F. Knoflach, et al., The Journal of Neuroscience, vol. 16, No. 21, pp. 6657-6664, “Modulation of Voltage-Gated Calcium Channels by Orphanin FQ in Freshly Dissociated Hippocampal Neurons”, Nov. 1, 1996.
T. Manabe, et al., Nature, vol. 394, pp. 577-581, “Facilitation of Long-Term Potentiation and Memory in Mice Lacking Nociceptin Receptors”, Aug. 6, 1998.
H. Matthes, et al., Molculear Pharmacology, vol. 50, pp. 447-450, “Functional Selectivity of Orphanin FQ for its Receptor Coexpressed With Potassium Channel Subunits in Xenopus Laevis Oocytes”, 1996.
J-C. Meunier, et al., Nature, vol. 377, pp. 532-535, “Isolation and Structure of the Endogenous Agonist of Opioid Receptor-Like ORL1Receptor”, Oct. 12, 1995.
J. S. Mogil, et al., Neuroscience Letters, vol. 214, pp. 131-134, “Functional Antagonism of μ-, δ- and κ-Opioid Antinociception by Orphanin FQ”, 1996.
J. S. Mogil, et al., Neuroscience, vol. 75, No. 2, pp. 333-337, “Orphanin FQ is a Functional Anti-Opioid Peptide”, 1996.
C. Mollereau, et al. , FEBS Letters, vol. 341, pp. 33-38, “ORL1, a Novel Member of the Opioid Receptor Family Cloning, Functional Expression and Localization”, 1994.
M. Nishi, et al., The EMBO Journal, vol. 16, No. 8, pp. 1858-1864, “Unrestrained Nociceptive Response and Disregulation of Hearing Ability in Mice Lacking the Nociceptin/Orphanin FQ Receptor”, 1997.
J. D. Pomonis, et al., NeuroReport, vol. 8, No. 1, pp. 369-371, “Orphanin FQ, Agonist of Orphan Opioid Receptor ORL1, Stimulates Feeding in Rats”, Dec. 20, 1996.
R. K. Reinscheid, et al., Science, vol. 270, pp. 792-794, “Orphanin FQ: A Neuropeptide that Activates an Opioidlike G Protein-Coupled Receptor”, Nov. 3, 1995.
N. Risch, et al., Angew. Chem., vol. 106, No. 23-24, pp. 2531-2533, “Diastereomerenreine Mannich-Basen Durch Addition Von Enaminen An Ternaere Iminiumsalze”, 1994.
J. Sandin, et al., European Journal of Neuroscience, vol. 9, pp. 194-197, “Short Communication Nociceptin-Orphanin FQ Microinjected into Hippocampus Impairs Spatial Learning in Rats”, 1997.
Y.-S. Shu, et al., Neuropeptides, vol. 32, No. 6, pp. 567-571, “Orphanin FQ/Nociceptin Modulates Glutamate- and Kainic Acid-Induced Currents in Acutely Isolated Rat Spinal Dorsal Horn Neurons”, 1998.
C. W. Vaughan, et al., British Journal of Phamacology, vol. 117, pp. 1609-1611, “Increase by the ORL1Receptor (Opioid Receptor-Like1) Ligand, Nociceptin, of Inwardly Rectifying K Conductance in Dorsal Raphe Nucleus Neurones”, 1996.
E. Winterfeldt, Synthesis, pp. 617-630, “Applications of Diisobutylaluminium Hydride (Dibah) and Triiso-Butylaluminium (Tiba) as Reducing Agents in Organic Synthesis”, Oct. 1975.
X-J. Xu, et al., NeuroReport, vol. 7, No. 13, pp. 2092-2094, “Nociceptin or Antinociceptin: Potent Spinal Antinociceptive Effect of Orphanin FQ/Nociceptin in the Rat”, Sep. 2, 1996.
T. Yamamoto, et al., Neuroscience, vol. 81, No. 1, pp. 249-254, “Analgesic Effect of Intrathecally Administered Nociceptin, an Opioid Receptor-Like1Receptor Agonist, in the Rat Formalin Test”, 1997.
T. Yamamoto, et al., Anesthesiology, vol. 87 No. 5, pp. 1145-1152, “Effects of Intrathecally Administered Nocicepin, an Opioid Receptor-Like1Receptor Agonist, and N-Methyl-D-Aspartate Receptor Antagonists on the Thermal Hyperalgesia Induced by Partial Sciatic Nerve Injury in the Rat”, Nov. 1997.
Englberger Werner
Sundermann Bernd
Wnendt Stephan
Anderson Rebecca
Gruenenthal GmbH
Saeed Kamal A.
LandOfFree
Use of substituted 4-amino-1-phenylbutan-2-ol compounds as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of substituted 4-amino-1-phenylbutan-2-ol compounds as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of substituted 4-amino-1-phenylbutan-2-ol compounds as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3530242